Schweizerhall prepares to acquire Cimex
Schweizerhall is poised to complete the acquisition of Cimex Pharma via a voluntary tender offer of €8.30 per Cimex share.
Schweizerhall is poised to complete the acquisition of Cimex Pharma via a voluntary tender offer of €8.30 per Cimex share.
The French Authorities (Autorite des Marches Financiers, AMF) gave its green light for the transaction on 23 March.
Subsequent to the tender offer, and subject to holding more than 95% of the capital of Cimex, Schweizerhall has the intention to request from the Euronext the delisting of Cimex Pharma.
Schweizerhall, based in Basle, Switzerland, is active in the pharmaceutical and chemical industries. Its pharma business unit offers development, registration, approval, production and packaging of generic drugs. It specialises in solid formulations and serves the European generics industry. Its chemistry business unit is a leading trader and distributor of chemical raw materials, intermediates, specialty chemicals and customised mixtures.